Janux Therapeutics (NASDAQ:JANX) Reaches New 1-Year Low – Should You Sell?

Janux Therapeutics, Inc. (NASDAQ:JANX) reached a new 52-week low on Tuesday . The company traded as low as $12.80 and last traded at $13.0330, with a volume of 343731 shares trading hands. The stock had previously closed at $13.76.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JANX. Stifel Nicolaus lowered their price objective on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, December 2nd. HC Wainwright cut their price objective on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, December 2nd. Wedbush reissued an “outperform” rating and issued a $45.00 target price (down from $76.00) on shares of Janux Therapeutics in a report on Tuesday, December 2nd. Bank of America reduced their price target on shares of Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, December 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Wednesday, October 8th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Janux Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $60.08.

Janux Therapeutics Trading Down 3.1%

The company has a market cap of $801.77 million, a P/E ratio of -7.92 and a beta of 2.88. The firm has a 50-day moving average of $19.42 and a 200 day moving average of $23.02.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.21. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.07 million. On average, equities analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, insider Charles M. Winter sold 2,401 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $32,965.73. Following the sale, the insider owned 77,721 shares in the company, valued at $1,067,109.33. This trade represents a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Thomas Diraimondo sold 2,505 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $34,393.65. Following the completion of the sale, the insider directly owned 124,425 shares of the company’s stock, valued at $1,708,355.25. This represents a 1.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 42,364 shares of company stock worth $972,185. Company insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC lifted its stake in Janux Therapeutics by 230.0% during the 2nd quarter. Squarepoint Ops LLC now owns 189,569 shares of the company’s stock valued at $4,379,000 after acquiring an additional 132,121 shares during the period. Quinn Opportunity Partners LLC increased its holdings in Janux Therapeutics by 15.4% during the second quarter. Quinn Opportunity Partners LLC now owns 59,893 shares of the company’s stock valued at $1,384,000 after buying an additional 8,000 shares during the last quarter. Geode Capital Management LLC raised its position in Janux Therapeutics by 15.5% in the second quarter. Geode Capital Management LLC now owns 902,312 shares of the company’s stock worth $20,845,000 after acquiring an additional 121,403 shares during the period. AlphaQuest LLC boosted its stake in shares of Janux Therapeutics by 3,658.9% during the 2nd quarter. AlphaQuest LLC now owns 9,698 shares of the company’s stock worth $224,000 after acquiring an additional 9,440 shares during the last quarter. Finally, Capital Fund Management S.A. bought a new stake in shares of Janux Therapeutics during the 2nd quarter valued at $757,000. 75.39% of the stock is currently owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.